4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Transcenta Holding Limited (6628) operates in the Biotechnology industry and is headquartered in Suzhou, China with about 155 employees. Its market capitalization is roughly CNY 475 million. In the fiscal year ended 2025-12-31, 6628 reported CNY 7M in revenue and (CNY 204M) in net income.
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People's Republic of China and the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 7M | CNY 11M | CNY 54M | CNY 102M | — |
| Gross Profit | CNY 2M | CNY 4M | CNY 14M | CNY 20M | — |
| Operating Income (EBIT) | (CNY 183M) | (CNY 244M) | (CNY 464M) | (CNY 422M) | — |
| Net Income | (CNY 204M) | (CNY 290M) | (CNY 463M) | (CNY 407M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 925M | CNY 1.2B | CNY 1.7B | CNY 2.1B | — |
| Total Liabilities | CNY 307M | CNY 449M | CNY 666M | CNY 661M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6628 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms